SecBot SecBot
PRESS-RELEASE ·Filed Apr 28, 2026

KNSA

Kiniksa Pharmaceuticals International, Plc
BULLISH
Impact 8/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised guidance and strong beat confirm accelerating ARCALYST adoption. Watch for KPL-387 Phase 2 data in 2H 2026 as the next major catalyst. The stock may gap up on this print given the magnitude of the beat and guidance raise.

DirectionBullish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
KNSA ▲ +17.08% at T+60d
LONG call ✓ call won +17.08% · α vs SPY +13.10% · entry $53.85 → $63.05
Entry = T+0 close
Apr 28, 2026
via day close
T+1d
-1.60%
call -1.60% · α -1.59%
$52.99
settled 6mo ago
T+5d
+7.00%
call +7.00% · α +5.31%
$57.62
settled 6mo ago
T+20d
-1.84%
call -1.84% · α -7.31%
$52.86
settled 5mo ago
T+60d
+17.08%
call +17.08% · α +13.10%
$63.05
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Kiniksa reported Q1 2026 revenue of $214.3M (56% YoY growth) and GAAP diluted EPS of $0.27, beating consensus EPS of $0.16. The company raised its 2026 ARCALYST net product revenue guidance to $930M-$945M from $900M-$920M, signaling accelerating commercial momentum.

Key Financial Metrics

EPS
$0.27
est $0.16 · +68.8%
Revenue
$214.3M
est $206.1M · +4.0% · +55.5% YoY
Rating
strong beat
Guidance
$930M-$945M
raised
Gross Margin
90.29%

Key Facts

  • Q1 2026 ARCALYST net product revenue $214.3M, up 56% YoY from $137.8M
  • GAAP diluted EPS $0.27 vs consensus $0.16 (beat by 68.8%)
  • 2026 ARCALYST revenue guidance raised to $930M-$945M from $900M-$920M
  • Net income $22.6M vs $8.5M in Q1 2025 (165% increase)
  • Cash balance $468.1M, no debt; cash flow positive on annual basis
  • KPL-387 Phase 2 data expected 2H 2026; Phase 3 pivotal trial initiation by year-end 2026

Financial Impact

Revenue guidance raised by $30M at midpoint; EPS beat of $0.11 vs consensus; net income more than doubled YoY

revenueepsguidancecash

Risk Factors

  • ARCALYST revenue concentration — single product risk
  • KPL-387 Phase 2 data readout in 2H 2026 carries binary risk
  • Operating expenses growing faster than revenue (49% vs 56%) may pressure margins

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3282473
16 reports for KNSA
Performance horizon
50% Hit rate @ T+60 2 of 4 directional calls Went positive at some point 4 of 4 best @ T+5▲ +4.54%Apr 6, 2026
Filters
Rows
Reports for KNSA — sortable, filterable
TypeNow
Oct 27, 2026
today
8-K
BULLISH ★ 6/10
$76.00awaiting T+60—$85.32 (+12.27%)
Oct 27, 2026
today
Press Release
BULLISH ★ 6/10
$75.00awaiting T+60—$85.32 (+13.76%)
Oct 22, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$76.73awaiting T+60—$85.32 (+11.20%)
Oct 22, 2026
4d ago
Press Release
NEUTRAL ★ 1/10
$80.79awaiting T+60—$85.32 (+5.61%)
Sep 3, 2026
7w ago
144
NEUTRAL ★ 2/10
$77.91awaiting T+60—$85.32 (+9.51%)
Jul 28, 2026
13w ago
8-K
BULLISH ★ 7/10
$79.44 $79.70▲ +0.33%▼ −4.02%$85.32 (+7.40%)
Jul 28, 2026
13w ago
Press Release
BULLISH ★ 7/10
$79.44 $79.70▲ +0.33%▼ −4.02%$85.32 (+7.40%)
May 26, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$51.84 $78.47▲ +51.37%▲ +49.49%$85.32 (+64.58%)
May 1, 2026
25w ago
8-K
NEUTRAL ★ 2/10
$57.62 $80.92▲ +40.44%▲ +38.58%$85.32 (+48.07%)
Apr 28, 2026
25w ago
144
BEARISH ★ 6/10
$52.99 $62.84▼ −18.59%▼ −14.48%$85.32 (−61.01%)
Showing 10 of 16

US Market Status

Market Open — Closes in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026